Company intelligence / Profile preview
Aptarion Biotech
Berlin, Berlin, Germanyaptarion.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate AON-D21 (an anti-C5a L-aptamer) shows strong preclinical efficacy in severe pneumonia and lung cancer models; currently recruiting and active in double-blind, placebo-controlled Phase 2 clinical trial for severe community-acquired pneumonia. Completed Phase 1 trial provided safety, tolerability, and PK data.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- AptamerRNA aptamerBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
NOXXON Pharma (technology license and IP transfer/spinout agreement for Spiegelmer/SPIEGELMER aptamer technology)
Beyond the preview
Go deeper on Aptarion Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aptarion Biotech.